Exelixis Looks To Early-Stage Option Rights As Low-Risk Pipeline Expansion Play

02 Nov 2022

The maker of Cabometyx wants to expand its oncology pipeline via deal-making but is wary of the high attrition rate in cancer. Option deals with Cybrexa and Sairopa may avoid some of that risk.

Busy pace — Exelixis is maintaining a busy pace with Cabometyx and two new deals • Source: Shutterstock

Exelixis, Inc. has entered into a pair of R&D collaboration and option deals for early-stage cancer candidates that it claims could offer both a first-in-class opportunity with a peptide-drug conjugate and a best-in-class opportunity to target SIRP-alpha in immuno-oncology, part of a lower-risk business development strategy, management explained during its same-day third quarter earnings call.

On the 1 November Q3 earnings call, Exelixis CEO Michael Morrissey explained that his company is employing a business development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

27 Jun 2025

• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut